Showing 9001-9010 of 10165 results for "".
- Modernizing Medicine Completes $12 Million Capital Raisehttps://practicaldermatology.com/news/20130111-modernizing_medicine_completes_12_million_capital_raise/2459639/Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, completed a $12 million capital raise, with a combination of equity capital and a senior bank debt facility. The company plans to use the funding to, among other things, acc
- Winter Rosacea Treatmentshttps://practicaldermatology.com/news/20130108-winter_rosacea_treatments/2459646/Winter weather and the associated heating systems can easily aggravate sensitive and rosacea-prone skin. With Rosacea Awareness Month coming up this April, the following products can help sooth and calm the redness and irritation associated with rosacea.
- DermOne Acquires Atlantic Dermatologyhttps://practicaldermatology.com/news/20130107-dermone_acquires_atlantic_dermatology/2459647/DermOne closed on the acquisition of Atlantic Dermatology of Wilmington, NC on December 31, 2012. Atlantic Dermatology specializes in cosmetic, laser, medical, and surgical dermatolo
- Perrigo Company Acquires Cobrek Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130102-perrigo_company_acquires_cobrek_pharmaceuticals_inc/2459651/Perrigo Company signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, Inc. for approximately $45 million on a cash-free and debt-free basis. The merge concludes a four-year collaborative partnership responsi
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at